Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.
A number of other research analysts also recently weighed in on the company. Jefferies Financial Group downgraded Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a report on Thursday, January 11th. Barclays lifted their price target on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $80.00.
Dr. Reddy’s Laboratories Price Performance
Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last issued its earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11. The business had revenue of $867.00 million for the quarter, compared to analysts’ expectations of $827.81 million. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%. On average, equities analysts anticipate that Dr. Reddy’s Laboratories will post 3.96 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of RDY. Lindbrook Capital LLC boosted its position in Dr. Reddy’s Laboratories by 10.1% during the first quarter. Lindbrook Capital LLC now owns 3,873 shares of the company’s stock valued at $284,000 after purchasing an additional 354 shares during the last quarter. First Trust Direct Indexing L.P. boosted its position in Dr. Reddy’s Laboratories by 2.4% during the first quarter. First Trust Direct Indexing L.P. now owns 10,634 shares of the company’s stock valued at $780,000 after purchasing an additional 251 shares during the last quarter. Artemis Investment Management LLP acquired a new stake in Dr. Reddy’s Laboratories during the first quarter valued at $594,000. Janiczek Wealth Management LLC boosted its position in Dr. Reddy’s Laboratories by 39.2% during the first quarter. Janiczek Wealth Management LLC now owns 6,177 shares of the company’s stock valued at $453,000 after purchasing an additional 1,740 shares during the last quarter. Finally, DGS Capital Management LLC boosted its position in Dr. Reddy’s Laboratories by 15.2% during the first quarter. DGS Capital Management LLC now owns 9,922 shares of the company’s stock valued at $728,000 after purchasing an additional 1,306 shares during the last quarter. Hedge funds and other institutional investors own 14.02% of the company’s stock.
About Dr. Reddy’s Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
Featured Stories
- Five stocks we like better than Dr. Reddy’s Laboratories
- Insider Selling Explained: Can it Inform Your Investing Choices?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- The Role Economic Reports Play in a Successful Investment Strategy
- Hilton Demonstrates Asset Light is Right for Investors
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.